Topics

As Sarepta Therapeutics waits for the FDA to announce an approval decision on a new drug to treat Duchenne muscular dystrophy, big questions hang over its top-selling medicine that's already on market. https://buff.ly/2Z7bpVh 

20:00 EDT 15 Aug 2019 | STAT

As Sarepta Therapeutics waits for the FDA to announce an approval decision on a new drug to treat Duchenne muscular dystrophy, big questions hang over its top-selling medicine that's already on market. https://buff.ly/2Z7bpVh 

Original Article: As Sarepta Therapeutics waits for the FDA to announce an approval decision on a new drug to treat Duchenne muscular dystrophy, big questions hang over its top-selling medicine that's already on market. https://buff.ly/2Z7bpVh 

NEXT ARTICLE

More From BioPortfolio on "As Sarepta Therapeutics waits for the FDA to announce an approval decision on a new drug to treat Duchenne muscular dystrophy, big questions hang over its top-selling medicine that's already on market. https://buff.ly/2Z7bpVh "

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Muscular Dystrophy
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...